Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Statkevich

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
Pageof 5